Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Rosie Z Yu"'
Autor:
Rosie Z Yu, Mark J Graham, Noah Post, Stan Riney, Thomas Zanardi, Shannon Hall, Jennifer Burkey, Colby S Shemesh, Thazha P Prakash, Punit P Seth, Eric E Swayze, Richard S Geary, Yanfeng Wang, Scott Henry
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 5, Iss C (2016)
Triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotides (ASOs) have greatly improved potency via receptor-mediated uptake. In the present study, the in vivo pharmacology of a 2′-O-(2-methoxyethyl)-modified ASO conjugated
Externí odkaz:
https://doaj.org/article/2b26807b841244429f7ffc38c01b9c47
Autor:
Colby S Shemesh, Rosie Z Yu, Hans J Gaus, Sarah Greenlee, Noah Post, Karsten Schmidt, Michael T Migawa, Punit P Seth, Thomas A Zanardi, Thazha P Prakash, Eric E Swayze, Scott P Henry, Yanfeng Wang
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 5, Iss C (2016)
Triantennary N-acetyl galactosamine (GalNAc3) is a high-affinity ligand for hepatocyte-specific asialoglycoprotein receptors. Conjugation with GalNAc3 via a trishexylamino (THA)-C6 cluster significantly enhances antisense oligonucleotide (ASO) potenc
Externí odkaz:
https://doaj.org/article/1de8c3f8738147bdba5db5c61c7a342f
Autor:
Rosie Z Yu, John S Grundy, Scott P Henry, Tae-Won Kim, Daniel A Norris, Jennifer Burkey, Yanfeng Wang, Andrew Vick, Richard S Geary
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 4, Iss C (2015)
Evaluation of species differences and systemic exposure multiples (or ratios) in toxicological animal species versus human is an ongoing exercise during the course of drug development. The systemic exposure ratios are best estimated by directly compa
Externí odkaz:
https://doaj.org/article/246f1041032e42dfa83f03452a855de3
Autor:
Michael Walsh, Claudette Bethune, Andrew Smyth, Jessica Tyrwhitt, Shiangtung W. Jung, Rosie Z. Yu, Yanfeng Wang, Richard S. Geary, Jeffrey Weitz, Sanjay Bhanot
Publikováno v:
Kidney International Reports, Vol 7, Iss 2, Pp 200-209 (2022)
Introduction: Patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) have an increased risk of thrombotic events and bleeding. Antisense reduction of factor XI (FXI) with IONIS-FXIRx is a novel strategy that may safely reduce the ri
Externí odkaz:
https://doaj.org/article/9d5c672fdff6474baf02354f5b056319
Autor:
Stefan Willmann, Eleonora Marostica, Nelleke Snelder, Alexander Solms, Markus Jensen, Maximilian Lobmeyer, Anthonie W. A. Lensing, Claudette Bethune, Erin Morgan, Rosie Z. Yu, Yanfeng Wang, Shiangtung W. Jung, Richard Geary, Sanjay Bhanot
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 890-901 (2021)
Abstract IONIS‐FXIRX (BAY2306001) is an antisense oligonucleotide that inhibits the synthesis of coagulation factor XI (FXI) and has been investigated in healthy volunteers and patients with end‐stage renal disease (ESRD). FXI‐LICA (BAY2976217)
Externí odkaz:
https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9
Autor:
Nicholas J. Viney, Shuling Guo, Li‐Jung Tai, Brenda F. Baker, Mariam Aghajan, Shiangtung W. Jung, Rosie Z. Yu, Sheri Booten, Heather Murray, Todd Machemer, Sebastien Burel, Sue Murray, Gustavo Buchele, Sotirios Tsimikas, Eugene Schneider, Richard S. Geary, Merrill D. Benson, Brett P. Monia
Publikováno v:
ESC Heart Failure, Vol 8, Iss 1, Pp 652-661 (2021)
Abstract Aims Amyloidogenic transthyretin (ATTR) amyloidosis is a fatal disease characterized by progressive cardiomyopathy and/or polyneuropathy. AKCEA‐TTR‐LRx (ION‐682884) is a ligand‐conjugated antisense drug designed for receptor‐mediat
Externí odkaz:
https://doaj.org/article/3297462a8e6e4c1081fbb6040b37c72e
Autor:
John K. Diep, Rosie Z. Yu, Nicholas J. Viney, Eugene Schneider, Shuling Guo, Scott Henry, Brett Monia, Richard Geary, Yanfeng Wang
Publikováno v:
British Journal of Clinical Pharmacology. 88:5389-5398
Transthyretin-mediated amyloidosis is a progressive and fatal disease caused by the build-up of misfolded transthyretin (TTR) protein. Eplontersen is a triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotide targeting TTR m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87cf398f01a3cd3a211509b8e0991145
https://doi.org/10.1111/bcp.15468
https://doi.org/10.1111/bcp.15468
Autor:
Sanjay Bhanot, Eleonora Marostica, Maximilian Lobmeyer, Nelleke Snelder, Erin E. Morgan, Anthonie W. A. Lensing, Richard S. Geary, Markus Jensen, Shiangtung W. Jung, Yanfeng Wang, Rosie Z. Yu, Stefan Willmann, Claudette Bethune, Alexander Solms
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 890-901 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
IONIS‐FXIRX (BAY2306001) is an antisense oligonucleotide that inhibits the synthesis of coagulation factor XI (FXI) and has been investigated in healthy volunteers and patients with end‐stage renal disease (ESRD). FXI‐LICA (BAY2976217) shares t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c833bb12274e461ae57144f261c44b4
https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9
https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9
Autor:
Yanfeng Wang, John K. Diep, Rosie Z. Yu, Eunju Hurh, Ewa Karwatowska‐Prokopczuk, Eugene Schneider, Scott Henry, Sanjay Bhanot, Richard S. Geary
Publikováno v:
Journal of clinical pharmacologyReferences.
The pharmacokinetics (PK) of 2'-O-methoxyethyl and phosphorothioate antisense oligonucleotides (ASOs), with or without N-acetyl galactosamine conjugation, have been well characterized following subcutaneous or intravenous drug administration. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60c46dc27f55a183d4b9afa6f7b0ecf
https://pubmed.ncbi.nlm.nih.gov/35801818
https://pubmed.ncbi.nlm.nih.gov/35801818
Autor:
Yanfeng Wang, Padma Narayanan, Daniel A. Norris, Richard S. Geary, Scott P. Henry, Tae-Won Kim, Brett P. Monia, Rosie Z. Yu
Publikováno v:
Nucleic Acid Therapeutics. 30:265-275
Inotersen (TEGSEDI™) is a 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide, intended for treating hereditary transthyretin (TTR) amyloidosis with polyneuropathy. The potential immunogenicity (IM) response to inotersen was evaluated in chron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bdd6fde5c778b60361c6e8fcb009283
https://doi.org/10.1089/nat.2020.0867
https://doi.org/10.1089/nat.2020.0867